ResearchBand-Aids Can Still Help Heal: The Role of Patient Financial Assistance Programs in Addressing Financial Toxicity
ResearchThe Role of Targetable Biomarker Alterations in Overall Survival for Non-Small Cell Lung Cancer (NSCLC) in a Large Integrated Health System
ResearchAccess to Financial Assistance Programs and Their Impact on Overall Spending on Oral Anticancer Medications at an Integrated Specialty Pharmacy
ResearchLay Healthcare Worker Financial Toxicity Intervention: A Pilot Financial Toxicity Screening and Referral Program
ResearchConsolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study
ResearchReceipt of Financial Assistance for Oral Targeted Therapy Among Older Adults with Advanced Non-Small Cell Lung Cancer: A Prospective Cohort Study
ResearchClinical Validity and Utility of Circulating Tumor DNA (ctDNA) Testing in Advanced Non-Small Cell Lung Cancer (aNSCLC): A Systematic Literature Review and Meta-Analysis
ResearchConsolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC
ResearchPrivate Payer and Medicare Coverage Policies for Use of Circulating Tumor DNA Tests in Cancer Diagnostics and Treatment
ResearchThe Costs and Inequities of Precision Medicine for Patients with Prostate Cancer: A Call to Action
ResearchThe Health Inequality Impact of Liquid Biopsy to Inform First-Line Treatment of Advanced Non-Small Cell Lung Cancer: A Distributional Cost-Effectiveness Analysis